Previous Close | 0.2450 |
Open | 0.2500 |
Bid | 0.2400 x N/A |
Ask | 0.2550 x N/A |
Day's Range | 0.2400 - 0.2600 |
52 Week Range | 0.0900 - 0.7350 |
Volume | |
Avg. Volume | 247,575 |
Market Cap | 13.81M |
Beta (5Y Monthly) | 2.93 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino")(www.drinkpromino.com), today announced that Dr. Patrick Gunning will assess the results of preclinical trials with various GLP-1 drugs and Promino in murine obesity models to improve muscle mass retention during weight loss.
Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") is pleased to announce it has retained award winning PhD Dr. Patrick Gunning to assess preclinical studies conducted on its patented formulation's mitigation of muscle loss in cancer patients. Dr. Gunning will be joining the Company as a special advisor on various preclinical studies over the next 12 months.
Promino Nutritional Sciences Inc (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or Promino") (www.drinkpromino.com) announces e-commerce listing activity on Amazon, Walmart.com, and eBay ahead of the June relaunch of Rejuvenate Muscle Activator™, one of the Company's flagship drink mix brands.